`
`FDA Approves Ibrutinib to Treat Chronic Graft Versus Host Disease
`
`FDA Approves Ibrutinib to Treat Chronic Graft
`Versus Host Disease
`
`New York, NY (August 3, 2017) – New York, NY – The U.S. Food and Drug Administration (FDA) announced it
`has approved the use of ibrutinib (Imbruvica ®) to treat patients with chronic graft versus host disease
`(cGVHD) who have not responded to at least one line of prior corticosteroid treatment. To date, there have
`been no previously approved treatments available for this condition, which effects patients whose immune
`system attacks healthy cells following allogeneic transplant.
`“Today’s approval of ibrutinib is an important advancement for patients suffering from cGVHD, as well as
`those who may be considering transplantation as a potential treatment option,” said Meghan Gutierrez, Chief
`Executive Officer of the Lymphoma Research Foundation. “This serious condition previously had limited
`treatment options, and today’s indication not only represents the first approval for graph verses host disease,
`but represents hope for patients who undergo an allogeneic transplant for better outcomes in managing this
`disease.”
`This marks the sixth approval for ibrutinib in use of lymphoma patients. The drug had previously been
`approved for use in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic
`lymphocytic leukemia/small lymphocytic lymphoma with 17p deletion, Waldenström macroglobulinemia,
`marginal zone lymphoma, and mantle cell lymphoma.
`For additional information on the expanded approval of ibrutinib, read the FDA press announcement here.
`For additional information on stem cell transplantation, download the Lymphoma Research Foundation’s
`Understanding the Stem Cell Transplantation Process booklet and Transplant in Lymphoma fact sheet at
`lymphoma.org/publications.
`About the Lymphoma Research Foundation
`The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization devoted to funding
`innovative research and serving the lymphoma community through a comprehensive series of education
`programs, outreach initiatives and patient services. To date, LRF has awarded nearly $60 million in
`lymphoma-specific research. For additional information on LRF’s research, education and services, visit
`lymphoma.org.
`Contact:
`Jake DiGregorio
`508-414-8853
`jdigregorio@lymphoma.org
`08/03/2017 | by Nichole Musumeci
`
`https://www.lymphoma.org/newsarchive/fda-approves-ibrtutinib-cgvhd/
`
`1/1
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
